Literature DB >> 10390530

The Wilms' tumor suppressor gene (wt1) product represses different functional classes of transcriptional activation domains.

T H Lee1, P Moffett, J Pelletier.   

Abstract

We have studied the ability of the wt1 tumor suppressor gene product to repress different classes of activation domains previously shown to stimulate the initiation and elongation steps of RNA polymerase II transcription in vivo. Repression assays revealed that WT1 represses all three classes of activation domains: Sp1 and CTF, which stimulate initiation (type I), human immunodeficiency virus type I Tat fused to a DNA-binding domain, which stimulates predominantly elongation (type IIA), and VP16, p53 and E2F1, which stimulate both initiation and elongation (type IIB). WT1 is capable of exerting its repression effect over a significant distance when positioned approximately 1700 bp from the core promoter. Deletion analysis of WT1 indicates that the responsible domain resides within the first 180 N-terminal amino acids of the protein. Nuclear run-ons analyzing the effects of WT1 on initiation of transcription demonstrate inhibition of this process. Our observations imply that WT1 can repress activators that stimulate initiation and/or elongation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390530      PMCID: PMC148503          DOI: 10.1093/nar/27.14.2889

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  2 in total

1.  Expression of connective tissue growth factor (CCN2) in desmoplastic small round cell tumour.

Authors:  A W Rachfal; M H Luquette; D R Brigstock
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

2.  BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1.

Authors:  Brian Carpenter; Kathryn J Hill; Marika Charalambous; Kate J Wagner; Diya Lahiri; Dominic I James; Jens S Andersen; Valérie Schumacher; Brigitte Royer-Pokora; Matthias Mann; Andrew Ward; Stefan G E Roberts
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.